Lung Cancer and the Case for Targeted Testing
Lung cancer ranks second among all cancers in the Philippines in terms of incidence and first in cancer-related mortality, according to 2022 GLOBOCAN data. Non-small cell lung cancer (NSCLC) accounts for approximately 85 percent of cases. Among Filipino NSCLC patients, the incidence of EGFR mutations is 49.4 percent — a strikingly high proportion that makes molecular testing not a luxury but a clinical necessity.
In March 2026, the Health Technology Assessment (HTA) Council released a preliminary recommendation for government financing of tissue-based EGFR PCR mutation testing for patients with non-squamous NSCLC, and for patients diagnosed with squamous NSCLC under 50 years old regardless of smoking history. The recommendation aligns with the Council’s earlier endorsement of tyrosine kinase inhibitor drugs — erlotinib, gefitinib, and afatinib — as financing the mutation test ensures proper selection of patients who will benefit from these targeted treatments.
Why EGFR Testing Changes the Treatment Paradigm
Before precision oncology, NSCLC patients received uniform chemotherapy regimens regardless of tumor biology. The discovery of EGFR mutations — and the development of drugs that specifically inhibit the mutated protein — transformed the treatment landscape for the subset of patients who carry them. Of the EGFR mutations observed in the Philippines, 54.7 percent are exon 19 deletions and 27.4 percent are exon 21 L858R substitutions. Both mutation types are strongly associated with response to tyrosine kinase inhibitors.
The HTA Council’s recommendation includes practical implementation considerations: the Department of Health and PhilHealth should assess the compatibility of specific test cartridges and kits with existing PCR machines at service providers. The Council also emphasized the need for healthcare personnel training to ensure efficient utilization of the testing technology. These details matter. A reimbursement decision without the laboratory infrastructure and trained workforce to execute it remains an abstract policy.
Theranostics and the Broader Precision Oncology Ecosystem
While EGFR testing for NSCLC represents a near-term policy win, the broader precision oncology ecosystem in the Philippines is expanding. St. Luke’s Medical Center became the first and only ICPO Clinical Theranostics Center of Excellence in the country in May 2025. Theranostics — a portmanteau of therapeutics and diagnostics — integrates molecular imaging with targeted therapy, allowing clinicians to both visualize and treat disease at the molecular level.
Dr. Eduardo Erasto Ongkeko, Head of the Department of Nuclear Medicine and Theranostics at St. Luke’s-Global City, described the approach as moving “beyond the traditional ‘one size fits all’ approach”. The center has been working to make advanced therapies such as peptide receptor radionuclide therapy and PSMA radioligand therapy accessible to patients facing financial challenges. Human rights lawyer and Akbayan Party List Representative Chel Diokno, speaking at a Theranostics Day event, underscored the equity dimension: “I hope we can make these treatments available not just to the privileged, but to everyone afflicted with these illnesses”.
The Financing Gap and the Path Forward
The HTA Council’s recommendation for EGFR testing is a critical step, but it covers one mutation, one cancer type, and one testing modality. The Philippines’ precision oncology ambitions extend further — to next-generation sequencing for acute myeloid leukemia, to comprehensive genomic profiling for solid tumors, and to pharmacogenomic testing that predicts drug response and toxicity across therapeutic areas.
Each of these technologies will require its own HTA evaluation, its own financing pathway, and its own implementation strategy. The EGFR testing recommendation provides a template: evidence appraisal, cost analysis, stakeholder consultation, and alignment with clinical practice guidelines. Whether that template can be replicated at the pace demanded by scientific progress remains the central question for Philippine precision oncology.
